Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Celiprolol in systemic hypertension.

W H Frishman1, W Flamenbaum, J Schoenberger

  • 1Albert Einstein College of Medicine, Bronx, New York.

The American Journal of Cardiology
|April 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying patients at high risk of decompensated liver disease through unscheduled care attendance data: a retrospective cohort study.

BMC gastroenterology·2026
Same author

Transanal mesorectal excision: early outcomes in Australia and New Zealand.

The British journal of surgery·2021
Same author

Droplet digital PCR quantification suggests that higher viral load correlates with improved survival in HPV-positive oropharyngeal tumours.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2020
Same author

Locoregional recurrences after transanal total mesorectal excision of rectal cancer during the exploration phase.

The British journal of surgery·2020
Same author

Warming and acidification threaten glass sponge Aphrocallistes vastus pumping and reef formation.

Scientific reports·2020
Same author

Clinical course and pancreas parenchyma sparing surgical treatment of severe pancreatic trauma.

Injury·2020
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Celiprolol, a novel beta-blocker, effectively lowers blood pressure in patients with hypertension. This study shows celiprolol is a safe and well-tolerated once-daily treatment with no adverse effects on plasma lipids.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Systemic hypertension is a prevalent cardiovascular condition requiring effective management.
  • Beta-adrenergic blocking agents are a cornerstone of antihypertensive therapy.
  • Celiprolol offers a unique profile as a beta 1-selective blocker with beta 2-agonist properties.

Purpose of the Study:

  • To evaluate the safety and efficacy of orally administered celiprolol in patients with mild to moderate systemic hypertension.
  • To compare the antihypertensive effects of celiprolol with placebo in a randomized, double-blind study.
  • To assess the impact of celiprolol on plasma lipids and lipoproteins.

Main Methods:

  • A placebo-controlled, double-blind, randomized, titration-to-effect study design was employed.
  • 91 patients with mild to moderate hypertension received either placebo or celiprolol (200-600 mg/day) for 6 weeks.

Related Experiment Videos

  • Blood pressure, heart rate, plasma lipids, and lipoproteins were monitored throughout the study.

    • Main Results:

    • Celiprolol significantly reduced both supine and standing systolic and diastolic blood pressure compared to placebo (p < 0.05).
    • A significant reduction in supine heart rate was observed with celiprolol treatment versus placebo (p < 0.05).
    • No detrimental effects on plasma lipids or lipoproteins were observed with celiprolol therapy.

    Conclusions:

    • Celiprolol is a safe, effective, and well-tolerated once-daily antihypertensive medication.
    • The drug demonstrates a favorable efficacy profile in managing mild to moderate systemic hypertension.
    • Celiprolol does not adversely affect plasma lipid profiles, making it a potentially valuable therapeutic option.